Heyholder
‹ Activism Filings

Hana Pharm. Co., Ltd. Q3 operating profit KRW 6.4 billion, down 23.4% from a year earlier

Hana Pharm. Co., Ltd.· Periodic Report

AI summary · Not investment advice

Hana Pharm sold KRW 59.4 billion in Q3 and earned KRW 6.4 billion from its main business, down 23.4% from a year earlier and 12.4% from the previous quarter.

Operating profit · 3 months

KRW 6.4 billion

Key facts

Revenue (3 months)
KRW 59.4 billion
Net income (3 months)
KRW 4.6 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 63.8 billion
Revenue (year to date)
KRW 182.6 billion
Operating profit (prior-year 3 months)
KRW 8.3 billion
Operating profit (year to date)
KRW 20.8 billion
Net income (prior-year 3 months)
KRW -4.3 billionNet loss in the same period last year
Net income (year to date)
KRW 23.0 billion

Commentary

AI commentary · Not investment advice

What happened

Hanall Pharmaceutical reported its third-quarter results on a standalone basis. Sales for the latest 3 months were KRW 59.4 billion. That is 6.8% lower than a year earlier and 2.5% lower than the previous quarter. Sales for the year so far are KRW 182.6 billion.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 6.4 billion. That is 23.4% lower than a year earlier, when it was KRW 8.3 billion. It is also 12.4% lower than the previous quarter. Operating profit for the year so far is KRW 20.8 billion.

What changes for shareholders

Net income (the final profit after taxes and all other items) for the 3 months was KRW 4.6 billion, a swing back to profit. A year earlier, the same period had a net loss of KRW 4.3 billion. Net income is 45.7% lower than the previous quarter. Net income for the year so far is KRW 23.0 billion.

Comments

No comments yet

Comments from shareholders will appear here.